Dror Bashan - 19 Dec 2025 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Joseph R. Magnas, Attorney-in-Fact
Issuer symbol: PLX
Transactions as of: 19 Dec 2025
Transactions value $: $101,360
Form type: 4
Filing time: 23 Dec 2025, 07:25:58 UTC
Previous filing: 04 Sep 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bashan Dror	PRESIDENT AND CEO, Director	C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, ISRAEL	/s/ Joseph R. Magnas, Attorney-in-Fact	23 Dec 2025	0001781450

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLX	Common Stock	Purchase	$101K	+56K	+42.26%	$1.81	189K	19 Dec 2025	Direct
holding	PLX	Common Stock						2.34M	19 Dec 2025	By Trust	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.